Prelude Capital Management’s Coherus Oncology, Inc. Common Stock CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-10,436
| Closed | -$76K | – | 1513 |
|
|
2022
Q2 | $76K | Sell |
10,436
-1,036
| -9% | -$7.55K | ﹤0.01% | 1234 |
|
|
2022
Q1 | $148K | Sell |
11,472
-1,641
| -13% | -$21.2K | ﹤0.01% | 1056 |
|
|
2021
Q4 | $209K | Sell |
13,113
-1,314
| -9% | -$20.9K | 0.01% | 1207 |
|
|
2021
Q3 | $232K | Sell |
14,427
-327
| -2% | -$5.26K | 0.01% | 969 |
|
|
2021
Q2 | $204K | Sell |
14,754
-946
| -6% | -$13.1K | 0.01% | 1104 |
|
|
2021
Q1 | $229K | Buy |
15,700
+4,600
| +41% | +$67.1K | 0.01% | 883 |
|
|
2020
Q4 | $193K | Hold |
11,100
| – | – | ﹤0.01% | 675 |
|
|
2020
Q3 | $204K | Buy |
11,100
+5,100
| +85% | +$93.7K | 0.01% | 498 |
|
|
2020
Q2 | $107K | Buy |
+6,000
| New | +$107K | 0.01% | 646 |
|
|
2017
Q3 | – | Sell |
-1,200
| Closed | -$17K | – | 1516 |
|
|
2017
Q2 | $17K | Buy |
1,200
+1,000
| +500% | +$14.2K | ﹤0.01% | 1181 |
|
|
2017
Q1 | $4K | Sell |
200
-3,100
| -94% | -$62K | ﹤0.01% | 1349 |
|
|
2016
Q4 | $93K | Buy |
3,300
+700
| +27% | +$19.7K | 0.01% | 821 |
|
|
2016
Q3 | $70K | Sell |
2,600
-300
| -10% | -$8.08K | 0.01% | 879 |
|
|
2016
Q2 | $49K | Buy |
2,900
+2,000
| +222% | +$33.8K | 0.01% | 963 |
|
|
2016
Q1 | $19K | Sell |
900
-900
| -50% | -$19K | ﹤0.01% | 1040 |
|
|
2015
Q4 | $41K | Sell |
1,800
-200
| -10% | -$4.56K | 0.01% | 1011 |
|
|
2015
Q3 | $40K | Sell |
2,000
-500
| -20% | -$10K | 0.01% | 1031 |
|
|
2015
Q2 | $72K | Buy |
2,500
+1,800
| +257% | +$51.8K | 0.01% | 944 |
|
|
2015
Q1 | $21K | Sell |
700
-800
| -53% | -$24K | ﹤0.01% | 1659 |
|
|
2014
Q4 | $24K | Buy |
+1,500
| New | +$24K | ﹤0.01% | 1583 |
|